Current treatment options for postmenopausal vaginal atrophy
Modern medicine has in the arsenal various options for treating this pathological condition, including systemic and topical hormone replacement therapy, the use of selective estrogen receptor modulators, vaginal dehydroepiandrosterone, use of lubricants and moisturizers, as well as non-drug therapies.
Vaginal atrophy - Diagnosis & treatment - Mayo Clinic
2021年9月17日 · To treat genitourinary syndrome of menopause, your doctor may first recommend over-the-counter treatment options, including: Vaginal moisturizers. Try a vaginal moisturizer (K-Y Liquibeads, Replens, Sliquid, others) to restore some moisture to your vaginal area. You may have to apply the moisturizer every few days.
Treatment of Vulvovaginal Atrophy | Gynecology - JAMA Network
This JAMA Insights Clinical Update discusses management options for women with vulvovaginal atrophy, focusing on the systemic safety of estrogen-based
Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment
2024年7月15日 · Treatment options include both hormonal and nonhormonal interventions. Treatment of GSM is reviewed here. Clinical manifestations and diagnosis of vaginal atrophy, as well as use of estrogen therapy for other menopausal symptoms, are discussed in detail separately. Recent guidelines from the Endocrine Society cover each of these issues [7].
Vaginal Atrophy: Causes, Symptoms, Diagnosis & Treatment - Cleveland Clinic
What are the hormonal treatment options for vaginal atrophy (GSM)? Estrogen therapy and dehydroepiandrosterone (DHEA) are the only hormone therapies for vaginal atrophy. Topical estrogen. Topical vaginal estrogen treats symptoms of vaginal atrophy without increasing levels of estrogen levels in your bloodstream.
Vulvovaginal Atrophy (Genitourinary Syndrome of Menopause)
Treatment of atrophy with estrogen is more effective than emollients and lubricants alone in improving symptoms.
Vulvovaginal Atrophy - Mayo Clinic Proceedings
Vulvovaginal atrophy, a common and often underreported condition, occurs in women who experience hypoestrogenic states. Systemic treatment, when prescribed for menopausal symptoms, may not be sufficient to control VVA. Local estrogens include creams, tablets, and rings, all of which are equally effective.
VVA treatments should ideally be initiated when symptoms commence and cause distress, rather than later, when symptoms may have become more severe and even a cause of intolerable distress for the woman’. It is estimated that just 25% of patients with VVA symptoms receive appropriate treatment.
Vulvovaginal Atrophy - PMC
Vulvovaginal atrophy, a common and often underreported condition, occurs in women who experience hypoestrogenic states. Systemic treatment, when prescribed for menopausal symptoms, may not be sufficient to control VVA. Local estrogens include creams, tablets, and rings, all of which are equally effective.
Efficacy and safety of ultra-low-dose Vagifem (10 mcg) - PMC
Vulvovaginal atrophy [VVA] is defined as inflammation of the vaginal epithelium due to atrophy secondary to decreased levels of circulating estrogen. There is currently only one approved method for the treatment of VVA, and that is the administration of exogenous estrogens.